Red Flags
- Chest pain with eGFR <30 — high mortality; troponin baseline often elevated, trend over hours rather than absolute value drives diagnosis[1]
- Acute pulmonary oedema in dialysis patient — distinguish volume overload from ACS by ECG and troponin trend; both can coexist[2]
- Atypical or absent chest pain in dialysis ACS — uraemic neuropathy and diabetes mask classical symptoms; have a low threshold for serial ECG and troponin[1]
- Bleeding risk markedly elevated with eGFR <30 — uraemic platelet dysfunction; balance antithrombotic intensity carefully[1]
First-line treatment
Interventions
- Early invasive strategy[1]Coronary angiography within 24–72 h for NSTE-ACS in CKD remains beneficial despite contrast risk; STEMI requires primary PCI without delay regardless of eGFR. Use renal-protective contrast strategy
First-line drug therapy
| Drug | Class | Adult | Paediatric | Notes |
|---|---|---|---|---|
| Aspirin[1] | Antiplatelet (loading) | 300 mg PO loading then 75–100 mg PO once daily | — | No renal adjustment. Continue lifelong unless contraindicated |
| Clopidogrel[1] | P2Y12 inhibitor | 300–600 mg loading then 75 mg once daily for 12 months | — | Preferred over ticagrelor or prasugrel in advanced CKD due to bleeding risk; no specific renal adjustment but caution if eGFR <15 |
| Atorvastatin[1] | HMG-CoA reductase inhibitor (high-intensity statin) | 40–80 mg PO once daily | — | Initiate during admission. No dose adjustment for CKD |
| Enoxaparin[1] | Low-molecular-weight heparin | 1 mg/kg SC BD; reduce to 1 mg/kg SC once daily if eGFR 15–30 mL/min; AVOID if eGFR <15 (use unfractionated heparin instead) | — | UFH preferred when eGFR <15 due to predictable clearance |
| Metoprolol succinate[1] | Beta-blocker | 25–200 mg PO once daily, titrate to heart rate 55–60 bpm | — | No renal adjustment. Initiate within 24 h if no contraindication |
Aspirin[1]
Antiplatelet (loading)
- Adult
- 300 mg PO loading then 75–100 mg PO once daily
- Paediatric
- —
No renal adjustment. Continue lifelong unless contraindicated
Clopidogrel[1]
P2Y12 inhibitor
- Adult
- 300–600 mg loading then 75 mg once daily for 12 months
- Paediatric
- —
Preferred over ticagrelor or prasugrel in advanced CKD due to bleeding risk; no specific renal adjustment but caution if eGFR <15
Atorvastatin[1]
HMG-CoA reductase inhibitor (high-intensity statin)
- Adult
- 40–80 mg PO once daily
- Paediatric
- —
Initiate during admission. No dose adjustment for CKD
Enoxaparin[1]
Low-molecular-weight heparin
- Adult
- 1 mg/kg SC BD; reduce to 1 mg/kg SC once daily if eGFR 15–30 mL/min; AVOID if eGFR <15 (use unfractionated heparin instead)
- Paediatric
- —
UFH preferred when eGFR <15 due to predictable clearance
Metoprolol succinate[1]
Beta-blocker
- Adult
- 25–200 mg PO once daily, titrate to heart rate 55–60 bpm
- Paediatric
- —
No renal adjustment. Initiate within 24 h if no contraindication
Safety-net
- Take all heart-attack medications daily even when feeling well — stopping any antiplatelet within the first year sharply raises stent-thrombosis and reinfarction risk[1]
- Watch for unusual bruising, black stools, or prolonged bleeding from cuts — kidney disease plus blood thinners means higher bleeding risk; report promptly to your clinician[2]
- If you are on dialysis, attend every session — fluid overload after a heart attack can mimic recurrent angina[2]
Referral criteria
- STEMI or NSTE-ACS with ongoing ischaemia, haemodynamic instability, or refractory arrhythmia regardless of eGFRCath lab for primary or early PCI[1]
- Stabilised NSTE-ACS in eGFR <30 — invasive vs conservative strategy decisionCardiology and nephrology shared decision making[1]
- Dialysis-dependent patient with refractory angina on optimal medical therapyCardiology heart team for revascularisation evaluation[1]
Clinical summary
Diagnostic and treatment considerations for ACS in patients with CKD, where atypical presentations and renal-modified drug dosing are common.
References
- 1.2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (CKD subgroup) and KDIGO 2024 CKD Clinical Practice Guideline (2025)
- 2.KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International (2024)